CoChat

Comparative cardiovascular safety of glucagon‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study

Patorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., Kim, S. C. · 2016 · Diabetes, Obesity and Metabolism
Cited by 31

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aims: To evaluate the comparative cardiovascular disease ( CVD ) safety of glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RAs ) in head‐to‐head comparisons with dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors, sulphonylureas or insulin, when added to metformin, as used in ‘real‐world’ patients with type 2 diabetes mellitus ( T2DM ). Methods: Within a large US commercial health plan database linked to laboratory test results, we identified three pairwise 1 : 1 propensity‐score‐matched cohorts of patients with T2DM aged ≥18 years treated with metformin who initiated a GLP ‐1 RA or a comparator, i.e. DPP ‐4 inhibitor (n = 35 534), second‐generation sulphonylureas (n = 28 138) or insulin (n = 47 068), between 2005 and 2013. We examined the association between drug initiation and a composite CVD endpoint, comprising hospitalizations for acute myocardial infarction, unstable angina, stroke or coronary revascularization. Results: During the course of 1 year, there were 13.9 and 13.7 CVD events per 1000 person‐years among propensity‐score‐matched initiators of GLP ‐1 RAs versus DPP ‐4 inhibitors [hazard ratio ( HR ) 1.02; 95% confidence interval ( CI ) 0.84–1.24]; and 12.1 versus 14.0 events among initiators of GLP ‐1 RAs versus sulphonylureas ( HR 0.86; 95% CI 0.69–1.08). The effect estimates for GLP ‐1 RAs versus insulin were sensitive to the adjustment for glycated haemoglobin, after which the HR was 1.01 (95% CI 0.73–1.41). Results were robust across several sensitivity analyses, including an as‐treated analysis considering up to 8.7 years of follow‐up. Conclusions: This large study, performing head‐to‐head comparisons of GLP ‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12665

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

Metadata

Authors
Patorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-05-02
Volume
18
Issue
8
Pages
755-765
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2307586345
Cited by
31
References
10
FWCI
3.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.